Mathew, Stephen O.2020-12-092020-12-092019-12https://hdl.handle.net/20.500.12503/29949To evaluate the hemoglobin (Hb) levels in 18 patients with anemia secondary to chronic kidney disease, the safety and efficacy of Drug B (HIF-PH inhibitor) was compared to the standard of care. The purpose was to assess whether Drug B improved baseline Hb levels after 52 weeks and evaluate adverse events (AEs) and total supplementation. Retrospective analysis of Hb values and supplemental treatments were analyzed to determine the efficacy of Drug B and AEs were assessed to determine safety. Overall, Drug B was effective at increasing Hb levels and had less AEs but required more supplementation. The efficacy of Drug B as it relates to pharmacokinetics still needs to be investigated.application/pdfenphase 3 clinical trialsecondary anemiachronic kidney diseaseRenal Insufficiency, ChronicAnemiaClinical Trial, Phase IIIThesis